Chronic Lymphocytic Leukemia Research Consortuim
CRC Research CRC Sites Clinical Trials For Patients Biorepository Publications & News How to Donate

Clinical Trials

Publications - CRC Program Related Publications

The CRC fostered collaborative interactions between members of the group (in bold font) that are reflected in the large numbers of joint publications between CRC investigators at different institutions. CRC publications listed in chronological order. The CRC has generated over 270 publicatios in the last 5 years. For more in formation on any of the CRC publications, goto PubMed.

2013 Publications (26)

  1. Balakrishnan K, Aggarwal S, Wierda W, Gandhi V. Bax and Bak are required for apogossypolone, a BH3-mimetic, induced apoptosis in chronic lymphocytic leukemia cells. Leukemia & lymphoma. 2013;54(5):1097-100. doi: 10.3109/10428194.2012.718344. PubMed PMID: 22866921.
  2. Balakrishnan K, Gandhi V. Bcl-2 antagonists: a proof of concept for CLL therapy. Investigational new drugs. 2013;31(5):1384-94. doi: 10.1007/s10637-013-0002-4. PubMed PMID: 23907405.
  3. Balakrishnan K, Gandhi V. Uncoupling endoplasmic reticulum stress and autophagy: a potential implication for chronic lymphocytic leukemia therapy. Leukemia & lymphoma. 2013;54(12):2581-3. doi: 10.3109/10428194.2013.803228. PubMed PMID: 23656199.
  4. Balatti V, Lerner S, Rizzotto L, Rassenti LZ, Bottoni A, Palamarchuk A, Cascione L, Alder H, Keating MJ, Kipps TJ, Pekarsky Y, Croce CM. Trisomy 12 CLLs progress through NOTCH1 mutations. Leukemia. 2013;27(3):740-3. doi: 10.1038/leu.2012.239. PubMed PMID: 22902365; PubMed Central PMCID: PMC3733494.
  5. Barile E, De SK, Feng Y, Chen V, Yang L, Ronai Z, Pellecchia M. Synthesis and SAR studies of dual AKT/NF-kappaB inhibitors against melanoma. Chemical biology & drug design. 2013;82(5):520-33. doi: 10.1111/cbdd.12177. PubMed PMID: 23790042; PubMed Central PMCID: PMC3966491.
  6. Blachly JS, Byrd JC. Emerging drug profile: cyclin-dependent kinase inhibitors. Leukemia & lymphoma. 2013;54(10):2133-43. doi: 10.3109/10428194.2013.783911. PubMed PMID: 23488658; PubMed Central PMCID: PMC3778156.
  7. Chen SS, Batliwalla F, Holodick NE, Yan XJ, Yancopoulos S, Croce CM, Rothstein TL, Chiorazzi N. Autoantigen can promote progression to a more aggressive TCL1 leukemia by selecting variants with enhanced B-cell receptor signaling. Proceedings of the National Academy of Sciences of the United States of America. 2013;110(16):E1500-7. doi: 10.1073/pnas.1300616110. PubMed PMID: 23550156; PubMed Central PMCID: PMC3631671.
  8. Cui B, Zhang S, Chen L, Yu J, Widhopf GF, 2nd, Fecteau JF, Rassenti LZ, Kipps TJ. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis. Cancer research. 2013;73(12):3649-60. doi: 10.1158/0008-5472.CAN-12-3832. PubMed PMID: 23771907; PubMed Central PMCID: PMC3832210.
  9. Fecteau JF, Messmer D, Zhang S, Cui B, Chen L, Kipps TJ. Impact of oxygen concentration on growth of mesenchymal stromal cells from the marrow of patients with chronic lymphocytic leukemia. Blood. 2013;121(6):971-4. doi: 10.1182/blood-2012-08-447813. PubMed PMID: 23255557; PubMed Central PMCID: PMC3567343.
  10. Ferrajoli A, Shanafelt TD, Ivan C, Shimizu M, Rabe KG, Nouraee N, Ikuo M, Ghosh AK, Lerner S, Rassenti LZ, Xiao L, Hu J, Reuben JM, Calin S, You MJ, Manning JT, Wierda WG, Estrov Z, O'Brien S, Kipps TJ, Keating MJ, Kay NE, Calin GA. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood. 2013;122(11):1891-9. doi: 10.1182/blood-2013-01-478222. PubMed PMID: 23821659; PubMed Central PMCID: PMC3779381.
  11. Gaudio E, Paduano F, Ngankeu A, Lovat F, Fabbri M, Sun HL, Gasparini P, Efanov A, Peng Y, Zanesi N, Shuaib MA, Rassenti LZ, Kipps TJ, Li C, Aqeilan RI, Lesinski GB, Trapasso F, Croce CM. Heat shock protein 70 regulates Tcl1 expression in leukemia and lymphomas. Blood. 2013;121(2):351-9. doi: 10.1182/blood-2012-09-457374. PubMed PMID: 23160471; PubMed Central PMCID: PMC3544116.
  12. Hertlein E, Beckwith KA, Lozanski G, Chen TL, Towns WH, Johnson AJ, Lehman A, Ruppert AS, Bolon B, Andritsos L, Lozanski A, Rassenti L, Zhao W, Jarvinen TM, Senter L, Croce CM, Symer DE, de la Chapelle A, Heerema NA, Byrd JC. Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease. PloS one. 2013;8(10):e76607. doi: 10.1371/journal.pone.0076607. PubMed PMID: 24130782; PubMed Central PMCID: PMC3793922.
  13. Hudson RS, Yi M, Volfovsky N, Prueitt RL, Esposito D, Volinia S, Liu CG, Schetter AJ, Van Roosbroeck K, Stephens RM, Calin GA, Croce CM, Ambs S. Transcription signatures encoded by ultraconserved genomic regions in human prostate cancer. Molecular cancer. 2013;12:13. doi: 10.1186/1476-4598-12-13. PubMed PMID: 23409773; PubMed Central PMCID: PMC3626580.
  14. Ji J, Mould DR, Blum KA, Ruppert AS, Poi M, Zhao Y, Johnson AJ, Byrd JC, Grever MR, Phelps MA. A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013;19(5):1269-80. doi: 10.1158/1078-0432.CCR-12-1092. PubMed PMID: 23300276; PubMed Central PMCID: PMC3845832.
  15. Mahoney E, Byrd JC, Johnson AJ. Autophagy and ER stress play an essential role in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. Autophagy. 2013;9(3):434-5. doi: 10.4161/auto.23027. PubMed PMID: 23422081; PubMed Central PMCID: PMC3590270.
  16. Mao Y, Triantafillou G, Hertlein E, Towns W, Stefanovski M, Mo X, Jarjoura D, Phelps M, Marcucci G, Lee LJ, Goldenberg DM, Lee RJ, Byrd JC, Muthusamy N. Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013;19(2):347-56. doi: 10.1158/1078-0432.CCR-12-2046. PubMed PMID: 23209030; PubMed Central PMCID: PMC3793126.
  17. Mraz M, Kipps TJ. MicroRNAs and B cell receptor signaling in chronic lymphocytic leukemia. Leukemia & lymphoma. 2013;54(8):1836-9. doi: 10.3109/10428194.2013.796055. PubMed PMID: 23597135.
  18. Payne PR, Pressler TR, Sarkar IN, Lussier Y. People, organizational, and leadership factors impacting informatics support for clinical and translational research. BMC medical informatics and decision making. 2013;13:20. doi: 10.1186/1472-6947-13-20. PubMed PMID: 23388243; PubMed Central PMCID: PMC3577661.
  19. Que X, Widhopf GF, 2nd, Amir S, Hartvigsen K, Hansen LF, Woelkers D, Tsimikas S, Binder CJ, Kipps TJ, Witztum JL. IGHV1-69-encoded antibodies expressed in chronic lymphocytic leukemia react with malondialdehyde-acetaldehyde adduct, an immunodominant oxidation-specific epitope. PloS one. 2013;8(6):e65203. doi: 10.1371/journal.pone.0065203. PubMed PMID: 23840319; PubMed Central PMCID: PMC3688726.
  20. Schwaederle M, Ghia E, Rassenti LZ, Obara M, Dell'Aquila ML, Fecteau JF, Kipps TJ. Subclonal evolution involving SF3B1 mutations in chronic lymphocytic leukemia. Leukemia. 2013;27(5):1214-7. doi: 10.1038/leu.2013.22. PubMed PMID: 23337928; PubMed Central PMCID: PMC3650490.
  21. Stebbins JL, Santelli E, Feng Y, De SK, Purves A, Motamedchaboki K, Wu B, Ronai ZA, Liddington RC, Pellecchia M. Structure-based design of covalent Siah inhibitors. Chemistry & biology. 2013;20(8):973-82. doi: 10.1016/j.chembiol.2013.06.008. PubMed PMID: 23891150; PubMed Central PMCID: PMC3763817.
  22. Stephens DM, Ruppert AS, Maddocks K, Andritsos L, Baiocchi R, Jones J, Johnson AJ, Smith LL, Zhao Y, Ling Y, Li J, Phelps MA, Grever MR, Byrd JC, Flynn JM. Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia. Leukemia research. 2013;37(10):1195-9. doi: 10.1016/j.leukres.2013.06.006. PubMed PMID: 23867058; PubMed Central PMCID: PMC3934299.
  23. Trotta R, Chen L, Costinean S, Josyula S, Mundy-Bosse BL, Ciarlariello D, Mao C, Briercheck EL, McConnell KK, Mishra A, Yu L, Croce CM, Caligiuri MA. Overexpression of miR-155 causes expansion, arrest in terminal differentiation and functional activation of mouse natural killer cells. Blood. 2013;121(16):3126-34. doi: 10.1182/blood-2012-12-467597. PubMed PMID: 23422749; PubMed Central PMCID: PMC3630828.
  24. Vamos M, Welsh K, Finlay D, Lee PS, Mace PD, Snipas SJ, Gonzalez ML, Ganji SR, Ardecky RJ, Riedl SJ, Salvesen GS, Vuori K, Reed JC, Cosford ND. Expedient synthesis of highly potent antagonists of inhibitor of apoptosis proteins (IAPs) with unique selectivity for ML-IAP. ACS chemical biology. 2013;8(4):725-32. doi: 10.1021/cb3005512. PubMed PMID: 23323685; PubMed Central PMCID: PMC3953502.
  25. Zanesi N, Balatti V, Riordan J, Burch A, Rizzotto L, Palamarchuk A, Cascione L, Lagana A, Dupuy AJ, Croce CM, Pekarsky Y. A Sleeping Beauty screen reveals NF-kB activation in CLL mouse model. Blood. 2013;121(21):4355-8. doi: 10.1182/blood-2013-02-486035. PubMed PMID: 23591791; PubMed Central PMCID: PMC3663428.
  26. Zhang S, Wu CC, Fecteau JF, Cui B, Chen L, Zhang L, Wu R, Rassenti L, Lao F, Weigand S, Kipps TJ. Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Proceedings of the National Academy of Sciences of the United States of America. 2013;110(15):6127-32. doi: 10.1073/pnas.1221841110. PubMed PMID: 23530247; PubMed Central PMCID: PMC3625269.

2012 Publications

  1. Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia. Sivina M, Hartmann E, Vasyutina E, Boucas JM, Breuer A, Keating MJ, Wierda WG, Rosenwald A, Herling M, Burger JA. Leukemia. 2012 Aug;26(8):1812-20. doi: 10.1038/leu.2012.63. Epub 2012 Mar 5. PMID: 22460735
  2. A Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative Disorders. Timmerman JM, Byrd JC, Andorsky DJ, Yamada R, Kramer J, Muthusamy N, Hunder N, Pagel JM. Clin Cancer Res. 2012 Aug 14. [Epub ahead of print] PMID: 22893631
  3. ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. Mahoney E, Lucas DM, Gupta SV, Wagner AJ, Herman SE, Smith LL, Yeh YY, Andritsos L, Jones JA, Flynn JM, Blum KA, Zhang X, Lehman A, Kong H, Gurcan M, Grever MR, Johnson AJ, Byrd JC. Blood. 2012 Aug 9;120(6):1262-73. Epub 2012 Jun 27. PMID: 22740450
  4. Hematologist/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Shanafelt TD, Kay NE, Rabe KG, Inwards DJ, Zent CS, Leis JF, Schwager SM, Thompson CA, Bowen DA, Witzig TE, Slager SL, Call TG. Cancer. 2012 Apr 1;118(7):1827-37. doi: 10.1002/cncr.26474. Epub 2011 Aug 26. PMID: 22009554
  5. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Hoellenriegel J, Coffey GP, Sinha U, Pandey A, Sivina M, Ferrajoli A, Ravandi F, Wierda WG, O'Brien S, Keating MJ, Burger JA. Leukemia. 2012 Jul;26(7):1576-83. doi: 10.1038/leu.2012.24. Epub 2012 Feb 7. PMID: 22362000
  6. Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression. Chuang HY, Rassenti L, Salcedo M, Licon K, Kohlmann A, Haferlach T, Foà R, Ideker T, Kipps TJ. Blood. 2012 Jul 26. [Epub ahead of print] PMID: 22837534
  7. The Impact of Initial Fludarabine Therapy on Transformation to Richter's Syndrome or Prolymphocytic Leukemia in Patients with Chronic Lymphocytic Leukemia: Analysis of an Intergroup Trial (CALGB 9011). Solh M, Rai KR, Peterson BL, Kolitz JE, Appelbaum FR, Tallman MS, Belch A, Larson RA, Morrison VA. Leuk Lymphoma. 2012 Aug 17.
  8. Single-nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans. Coombs CC, Rassenti L, Falchi L, Slager SL, Strom SS, Ferrajoli A, Weinberg JB, Kipps TJ, Lanasa MC. Blood. 2012 Jun 28. [Epub ahead of print] PMID: 22745306
  9. Germline copy number variation associated with Mendelian inheritance of CLL in two families. Brown JR, Hanna M, Tesar B, Pochet N, Vartanov A, Fernandes SM, Werner L, Ash M, Roden CA, Macconaill L, Hainz U, Longtine J, Wang YE, Correll M, Van de Peer Y, Regev A, Wu C, Neuberg D, Freedman AS. Leukemia. 2012
  10. The downregulation of miR-125b in chronic lymphocytic leukemias leads to metabolic adaptation of cells to a transformed state. Tili E, Michaille JJ, Luo Z, Volinia S, Rassenti LZ, Kipps TJ, Croce CM. Blood. 2012 Jun 21. [Epub ahead of print] PMID: 22723551
  11. Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Byrd JC, Kipps TJ, Flinn IW, Cooper M, Odenike O, Bendiske J, Rediske J, Bilic S, Dey J, Baeck J, O'Brien S. Leuk Lymphoma. 2012 Jun 12. [Epub ahead of print] PMID: 22475052
  12. Quantitative DNA Methylation Analysis Identifies a Single CpG Dinucleotide Important for ZAP-70 Expression and Predictive of Prognosis in Chronic Lymphocytic Leukemia. Claus R, Lucas DM, Stilgenbauer S, Ruppert AS, Yu L, Zucknick M, Mertens D, Bühler A, Oakes CC, Larson RA, Kay NE, Jelinek DF, Kipps TJ, Rassenti LZ, Gribben JG, Döhner H, Heerema NA, Marcucci G, Plass C, Byrd JC. J Clin Oncol. 2012 Jul 10;30(20):2483-91. Epub 2012 May 7. PMID: 22564988
  13. Phase 2 trial of daily, oral polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Shanafelt TD, Call TG, Zent CS, Leis JF, Laplant B, Bowen DA, Roos M, Laumann K, Ghosh AK, Lesnick C, Lee MJ, Yang CS, Jelinek DF, Erlichman C, Kay NE. Cancer. 2012 Jul 3. doi: 10.1002/cncr.27719. [Epub ahead of print] PMID: 22760587
  14. Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule. Castro JE, Melo-Cardenas J, Urquiza M, Barajas-Gamboa JS, Pakbaz RS, Kipps TJ. Cancer Res. 2012 Jun 15;72(12):2937-48. Epub 2012 Apr 13. PMID: 22505652
  15. Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Byrd JC, Kipps TJ, Flinn IW, Cooper M, Odenike O, Bendiske J, Rediske J, Bilic S, Dey J, Baeck J, O'Brien S. Leuk Lymphoma. 2012 Jun 12. [Epub ahead of print] PMID: 22475052
  16. Targeting the B Cell Receptor Pathway in Chronic Lymphocytic Leukemia. Davids MS, Brown JR. Leuk Lymphoma. 2012 May 23. [Epub ahead of print] PMID: 22616724
  17. Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression. Melo-Cardenas J, Urquiza M, Kipps TJ, Castro JE. Cancer Gene Ther. 2012 May;19(5):336-44. doi: 10.1038/cgt.2012.6. Epub 2012 Mar 9. PMID: 22402624
  18. Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL). Palamarchuk A, Yan PS, Zanesi N, Wang L, Rodrigues B, Murphy M, Balatti V, Bottoni A, Nazaryan N, Alder H, Rassenti L, Kipps TJ, Freitas M, Croce CM, Pekarsky Y. Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2555-60. Epub 2012 Jan 30. PMID: 22308499
  19. Mechanisms and consequences of the loss of PHLPP1 phosphatase in chronic lymphocytic leukemia (CLL). O'Hayre M, Niederst M, Fecteau JF, Nguyen VM, Kipps TJ, Messmer D, Newton AC, Handel TM. Leukemia. 2012 Jul;26(7):1689-92. doi: 10.1038/leu.2012.6. Epub 2012 Jan 12. No abstract available. PMID: 22237780
  20. Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen. Steininger C, Widhopf GF 2nd, Ghia EM, Morello CS, Vanura K, Sanders R, Spector D, Guiney D, Jäger U, Kipps TJ. Blood. 2012 Mar 8;119(10):2293-301. Epub 2012 Jan 10. PMID: 22234695 [
  21. Structure and function of the hematopoietic cancer niche: focus on chronic lymphocytic leukemia. Fecteau JF, Kipps TJ. Front Biosci (Schol Ed). 2012 Jan 1;4:61-73. PMID: 22202043
  22. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, Carney DA, He SZ, Huang DC, Xiong H, Cui Y, Busman TA, McKeegan EM, Krivoshik AP, Enschede SH, Humerickhouse R. J Clin Oncol. 2012 Feb 10;30(5):488-96. Epub 2011 Dec 19. PMID: 22184378
  23. NOTCH1 mutations in CLL associated with trisomy 12. Balatti V, Bottoni A, Palamarchuk A, Alder H, Rassenti LZ, Kipps TJ, Pekarsky Y, Croce CM. Blood. 2012 Jan 12;119(2):329-31. Epub 2011 Nov 15. PMID: 22086416
  24. Tcl1 interacts with Atm and enhances NF-κB activation in hematologic malignancies. Gaudio E, Spizzo R, Paduano F, Luo Z, Efanov A, Palamarchuk A, Leber AS, Kaou M, Zanesi N, Bottoni A, Costinean S, Rassenti LZ, Nakamura T, Kipps TJ, Aqeilan RI, Pekarsky Y, Trapasso F, Croce CM. Blood. 2012 Jan 5;119(1):180-7. Epub 2011 Nov 7. PMID: 22065599
  25. Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1). Fecteau JF, Bharati IS, O'Hayre M, Handel TM, Kipps TJ, Messmer D. Mol Med. 2012 Feb 10;18(1):19-28. doi: 10.2119/molmed.2011.00164. PMID: 21979753
  26. ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia. Broome HE, Rassenti LZ, Wang HY, Meyer LM, Kipps TJ. Leuk Res. 2011 Oct;35(10):1390-4. Epub 2011 Aug 2. PMID: 21813176

PubMed comprises more than 20 million citations for biomedical literature from MEDLINE, life science journals, and online books. Using the PMID you can search for the full articles!

Publication listings for the CRC 2011 - 2006

  1. Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso M, Rossi S, Barbarotto E, Cimmino A, Adair B, Wojcik S, Valeri N, Calore F, Sampath D, Fanni F, Vannini I, Musuraca G, Dell’Aquila M, Alder H, Davuluri R, Rassenti L, Gegrini M, Nakamara T, Amadori D, Kay N, Rai K, Keating M, Kipps T, Calin G, Croce C. Association of MicorRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.  JAMA 2011:305(1):59-67. PMID: 21205967
  2. Wierda WG, Kipps TJ, Keating MJ, Brown JR, Gribben JG, Browning M, Rassenti LZ, Greaves AW, Neuberg D, O'Brien SM. Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer 2011 Jan 1:117(1):116-24. PMID: 20806349
  3. Slager SL, Rabe KG, Achenbach SJ, Vachon CM, Goldin LR, Strom SS, Lanasa MC, Spector LG, Rassenti LZ, Leis JF, Camp NJ, Glenn M, Kay NE, Cunningham JM, Hanson CA, Marti GE, Weinberg JB, Morrison VA, Link BK, Call TG, Caporaso NE, Cerhan JR. Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. Blood. 2010 Dec 3. [Epub ahead of print] PMID: 21131588
  4. Kay NE, Eckel-Passow JE, Braggio E, Vanwier S, Shanafelt TD, Van Dyke DL, Jelinek DF, Tschumper RC, Kipps T, Byrd JC, Fonseca R. Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. Cancer Genet Cytogenet. 2010 Dec;203(2):161-8. PMID: 21156228
  5. Smoley SA, Van Dyke DL, Kay NE, Heerema NA, Dell' Aquila ML, Dal Cin P, Koduru P, Aviram A, Rassenti L, Byrd JC, Rai KR, Brown JR, Greaves AW, Eckel-Passow J, Neuberg D, Kipps TJ, Dewald GW. Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium. Cancer Genet Cytogenet. 2010 Dec;203(2):141-8. PMID: 21156226
  6. Heerema NA, Byrd JC, Dal Cin PS, Dell' Aquila ML, Koduru PR, Aviram A, Smoley SA, Rassenti LZ, Greaves AW, Brown JR, Rai KR, Kipps TJ, Kay NE, Van Dyke DL; Chronic Lymphocytic Leukemia Research Consortium. Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study. Cancer Genet Cytogenet. 2010 Dec;203(2):134-40. PMID: 21156225
  7. Nana-Sinkam SP, Croce CM. MicroRNA in chronic lymphocytic leukemia: transitioning from laboratory-based investigation to clinical application. Cancer Genet Cytogenet. 2010 Dec;203(2):127-33. PMID: 21156224
  8. Wang L, Harshman SW, Liu S, Ren C, Xu H, Sallans L, Grever M, Byrd JC, Marcucci G, Freitas MA. Assaying pharmacodynamic endpoints with targeted therapy: flavopiridol and 17AAG induced dephosphorylation of histone H1.5 in acute myeloid leukemia. Proteomics. 2010 Dec;10(23):4281-92. PMID: 21110323
  9. Zhang L, Murray F, Rassenti LZ, Pu M, Kelly C, Kanter JR, Greaves A, Messer K, Kipps TJ, Insel PA. Cyclic nucleotide phosphodiesterase 7B mRNA: an unfavorable characteristic in chronic lymphocytic leukemia. Int J Cancer. 2010 Nov 30. [Epub ahead of print] PMID: 21120911
  10. Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, Lapushin R, Xiao L, Huang X, Werner L, Neuberg D, Kantarjian H, O'Brien S, Wierda WG, Keating MJ, Rosenwald A, Burger JA. CCL3 (MIP-1{alpha}) plasma levels and the risk for disease progression in chronic lymphocytic leukemia (CLL). Blood 2010 Nov 29 [Epub ahead of print] PMID: 21115978
  11. Wierda WG, Castro JE, Aguillon R, Sampath D, Jalayer A, McMannis J, Prussak CE, Keating M, Kipps TJ. A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154. Leukemia. 2010 Nov;24(11):1893-900. PMID: 20882050
  12. Blum W, Klisovic RB, Becker H, Yang X, Rozewski DM, Phelps MA, Garzon R, Walker A, Chandler JC, Whitman SP, Curfman J, Liu S, Schaaf L, Mickle J, Kefauver C, Devine SM, Grever MR, Marcucci G, Byrd JC. Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol. 2010 Nov 20;28(33):4919-25. Epub 2010 Oct 18. PMID: 20956622
  13. Messmer D, Fecteau JF, O'Hayre M, Bharati IS, Handel TM, Kipps TJ. Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to  CXCL12 that are sensitive to inhibition by sorafenib. Blood. 2010 Nov 15. [Epub ahead of print] PMID: 21079155
  14. Zhang W, Kater AP, Widhopf GF, 2nd, Chuang HY, Enzler T, James DF, Poustovoitov M, Tseng PH, Janz S, Hoh C, Herschman H, Karin M, Kipps TJ. B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2010 Nov 2;107(44):18956-60. PMID: 19755673
  15. Ni W, Ji J, Dai Z, Papp A, Johnson AJ, Ahn S, Farley KL, Lin TS, Dalton JT, Li X, Jarjoura D, Byrd JC, Sadee W, Grever MR, Phelps MA. Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition. PLoS One. 2010 Nov 1;5(11):e13792. PMID: 21072184
  16. Payne PR, Niland J, Embi PJ. Foundational Biomedical Informatics Research in the Clinical and Translational[AWG1] <#_msocom_1>   Science Era:  A Call to Action.  Journal of the American Medical Informatics Association (JAMIA). November 2010. PMID: 21044361
  17. Hertlein E, Wagner AJ, Jones J, Lin TS, Maddocks KJ, Towns WH 3rd, Goettl VM, Zhang X, Jarjoura D, Raymond CA, West DA, Croce CM, Byrd JC, Johnson AJ. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood. 2010 Jul 8;116(1):45-53. Epub 2010 Mar 29. PMID: 20351313
  18. Setlur SR, Ihm C, Tchinda J, Shams S, Werner L, Cho EK, Thompson C, PhillipsK, Rassenti LZ, Kipps TJ, Neuberg D, Freedman AS, Lee C, Brown JR. Comparison of familial and sporadic chronic lymphocytic leukaemia using high resolution array comparative genomic hybridization. Br J Haematol. 2010 Nov;151(4):336-45. PMID: 20812997
  19. Riches JC, Ramsay AG, Gribben JG. T-cell function in chronic lymphocytic leukaemia. Semin Cancer Biol. 2010 Dec;20(6):431-8. Epub 2010 Oct 27. PMID: 20920582
  20. Chen R. Guo L. Chen Y, Jiang Y, Wierda W, Plunkett, W. Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. Blood. 2010 Oct 22. [Epub ahead of print] PMID: 20971952
  21. Ramaswamy B, Phelps MA, Baiocchi R, Bekaii-Saab T, Ni W, Lai JP, Wolfson A, Lustberg ME, Wei L, Wilkins D, Campbell A, Arbogast D, Doyle A, Byrd JC, Grever MR, Shah MH. A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors. Invest New Drugs. 2010 Oct 12. [Epub ahead of print] PMID: 20938713
  22. Wierda WG, Chiorazzi N, Dearden C, Brown JR, Montserrat E, Shpall E, Stilgenbauer S, Muneer S, Grever M. Chronic lymphocytic leukemia: new concepts for future therapy. Clin Lymphoma Myeloma Leuk. 2010 Oct;10(5):369-78. PMID: 21030350
  23. Brown JR, Abramson J, Hochberg E, Mikler E, Dalton V, Werner L, Reynolds H, Thompson C, McDonough SM, Kuang Y, Ritz J, Neuberg D, Freedman AS. A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL. Leukemia. 2010 Nov;24(11):1972-5. Epub 2010 Sep 16. PMID: 20844565
  24. Parikh SA, Bhusal Y, Faderl SH, Wierda WG, O'Brien S, Kantarjian H, Adachi JA, Burger JA. The great imitator: systemic nocardiosis mimicking Richter's transformation in relapsed chronic lymphocytic leukemia. J Clin Oncol. 2010 Dec 10;28(35):e732-4. Epub 2010 Sep 7. PMID: 20823404
  25. Goldin LR, Lanasa MC, Slager SL, Cerhan JR, Vachon CM, Strom SS, Camp NJ, Spector LG, Leis JF, Morrison VA, Glenn M, Rabe KG, Achenbach SJ, Algood SD, Abbasi F, Fontaine L, Yau M, Rassenti LZ, Kay NE, Call TG, Hanson CA, Weinberg JB, Marti GE, Caporaso NE. Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families. Br J Haematol. 2010 Oct;151(2):152-8. doi: 10.1111/j.1365-2141.2010.08339.x. Epub 2010 Aug 25. PMID: 20738309
  26. Lin TS, Donohue KA, Byrd JC, Lucas MS, Hoke EE, Bengtson EM, Rai KR, Atkins JN, Link BK, Larson RA. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. J Clin Oncol. 2010 Oct 10;28(29):4500-6. Epub 2010 Aug 9. PMID: 20697069
  27. Gribben J, Rosenwald A, Gascoyne R, Lenz G. Targeting the microenvironment. Leuk Lymphoma. 2010 Aug;51 Suppl 1:34-40. PMID: 20815761
  28. Admirand JH, Knoblock RJ, Coombes KR, Tam C, Schlette EJ, Wierda WG, Ferrajoli A, O'Brien S, Keating MJ, Luthra R, Medeiros LJ, Abruzzo LV. Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression. Mod Pathol. 2010 Nov;23(11):1518-23. Epub 2010 Jul 23. PMID: 20657554
  29. Conde L, Halperin E, Akers NK, Brown KM, Smedby KE, Rothman N, Nieters A, Slager SL, Brooks-Wilson A, Agana L, Riby J, Liu J, Adami HO, Darabi H, Hjalgrim H, Low HQ, Humphreys K, Melbye M, Chang ET, Glimelius B, Cozen W, Davis S, Hartge P, Morton LM, Schenk M, Wang SS, Armstrong B, Kricker A, Milliken S, Purdue MP, Vajdic CM, Boyle P, Lan Q, Zahm SH, Zhang Y, Zheng T, Becker N, Benavente Y, Boffetta P, Brennan P, Butterbach K, Cocco P, Foretova L, Maynadié M, de Sanjosé S, Staines A, Spinelli JJ, Achenbach SJ, Call TG, Camp NJ, Glenn M, Caporaso NE, Cerhan JR, Cunningham JM, Goldin LR, Hanson CA, Kay NE, Lanasa MC, Leis JF, Marti GE, Rabe KG, Rassenti LZ, Spector LG, Strom SS, Vachon CM, Weinberg JB, Holly EA, Chanock S, Smith MT, Bracci PM, Skibola CF. Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet. 2010 Aug;42(8):661-4. Epub 2010 Jul 18. PMID: 20639881
  30. Santanam U, Zanesi N, Efanov A, Costinean S, Palamarchuk A, Hagan JP, Volinia S, Alder H, Rassenti L, Kipps T, Croce CM, Pekarsky Y. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc Natl Acad Sci U S A. 2010 Jul 6;107(27):12210-5. PMID:20566844
  31. Lucas DM, Alinari L, West DA, Davis ME, Edwards RB, Johnson AJ, Blum KA, Hofmeister CC, Freitas MA, Parthun MR, Wang D, Lehman A, Zhang X, Jarjoura D, Kulp SK, Croce CM, Grever MR, Chen CS, Baiocchi RA, Byrd JC. The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo. PLoS One. 2010 Jun 3;5(6):e10941. PMID: 20532179
  32. Payne PR, Embi PJ, Johnson SB, Mendonca E, Starren JB. Improving the Usability of Clinical Trial Participant Tracking Tools Using Knowledge-anchored Design Methodologies. Journal of Applied Clinical Informatics.  June, 2010.
  33. Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, Marchesini J, Mascellani N, Sana ME, Jarour R, Desponts C, Teitell M, Baffa R, Aqeilan R, Nickoloff B, TaccioliC, Garzon R, Di Leva G, Fabbri M, Catozzi M, Previati M, Ambs S, Palumbo T, Garofalo M, Veronese A, Bottoni A, Gasparini P, Iorio MV, Harris CC, Visone R, Pekarsky Y, de la Chapelle A, Bloomston M, Dillhoff M, Rassenti LZ, Kipps TJ, Huebner K, Pichiorri F, Lenze D, Cairo S, Buendia M-A, Pineau P, Dejean A, Zanesi N, Rossi S, Calin G, Liu C-G, Palatini J, Negrini M, Vecchione A, Rosenberg A, Croce CM. Reprogramming of miRNA networks in cancer and leukemia.  Genome Res. 20(5):589-99, May 2010. PMID: 20439436
  34. Payne PR, Borlawsky TB, Langella S, Snider M, Barrett MC, Nguyen-Pham T, Greaves AW. The TRITON Project: Design and Implementation of an Integrative Clinical and Translational Research Information Management Platform. AMIA Proc. 2010
  35. Zhang J, Ding L, Keen-Circle K, Borlawsky TB, Xiang Y, Ozer G, Jin R, Payne PR, Huang K. Predicting Biomarkers for Chronic Lymphocytic Leukemia Using Gene      Co-expression Network Analyses for ZAP70. BMC Bioinformatics. 2010. PMID: 21044363
  36. Payne PR, Huang K, Keen-Circle K, Kundu A, Zhang J, Borlawsky TB. Multi-dimensional Discovery of Biomarker and Phenotype Complexes. BMC Bioinformatics. 2010. PMID: 21044361
  37. Ghanem H, Jabbour E, Faderl S, Ghandhi V, Plunkett W, Kantarjian H. Clofarabine in leukemia. Expert Rev Hematol. 2010 Feb;3(1):15-22. PMID: 21082931
  38. Liu X, Wang Y, Benaissa S, Matsuda A, Kantarjian H, Estrov Z, Plunkett W. Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the anti-leukemia agent, CNDAC. Blood, 2010, 116:1737-46. PMID: 20479284
  39. Balakrishnan K, Burger JA, Quiroga MP, Henneberg M, Ayres ML, Wierda WG, Gandhi V. Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. Blood. 2010;116(7):1083-91. PMID: 20442367
  40. Chen R. Chubb S, Cheng T, Hawtin R, Gandhi V, Plunkett, W. Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line. Cancer Res. 2010; 70(16):6587-97. PMID: 20663900
  41. Balakrishnan K, Verma V, O'Brien S, Kilpatrick JM, Chen Y, Tyler BF, Bickel S, Bantia S, Keating MJ, Kantarjian H, Gandhi V, Ravandi V. Phase II and pharmacodynamic study of oral forodesine in patients with advanced and/or fludarabine-treated chronic lymphocytic leukemia. Blood. 2010;116(6):886-92. PMID: 20427701
  42. Chen R, Plunkett W. Strategy to induce of apoptosis and circumvent resistance in chronic lymphocytic leukemia. Best Pract. Res. Clin. Hematol. 23:155-166, 2010. PMID: 20620979
  43. Volinia S, Visone R, Galasso M, Rossi E, Croce CM.  Identification of microRNA activity by Targets’ Reverse Expression. Bioinformatics. 2010;26(1): 91-97. PMID: 19897564
  44. Palamarchuk A, Efanov A, Nazaryan N, Santanam U, Alder H, Rassenti L, Kipps T, Croce CM, Pekarsky Y.  13q14 deletions in CLL involve cooperating tumor suppressors.  Blood. 2010;115(19):3916-3922. PMID: 20071661
  45. Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, Liu S, Schwind S, Santhanam R, Hickey CJ, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, Huettner CS, Bhatia R, Roy DC, Liebhaber SA, Caligiuri MA, Marcucci G, Garzon R, Croce CM, Calin GA, Perrotti D.  miR-328 functions as anRNAdecoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell. 2010;140:652-65. PMID: 20211135
  46. Efanov A, Zanesi N, Nazaryan N, Santanam U, Palamarchuk A, Croce CM, Pekarsky Y. CD5+CD23+ leukemic cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation. Leukemia. 2010;24(5):970-975. PMID: 20357824
  47. Tong W, Chen R, Plunkett W, Siegel D, Sinha R, Harvey R, Badros A, Popplewell L, Coutre S, Fox J, Mahadocon K, Chen T, Kegley P, Hoch U, Wierda W. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7 and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia (CLL) and multiple myeloma (MM)) J. Clin. Oncol. 28:3015-22. PMID: 20479412
  48. Tong W, Chen R, Plunkett W, Siegel D, R. S, Harvey R, Badros A, Popplewell L, Coutre SE, Fox JA, Mahadocon K, Chen T, Kegley P, Hoch U, Wierda W. Phase I and pharmacologic study of SNS-032, a potenet and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lynphocytic leukemia. Best Pract Res Clin Haematol 2010; In Press.
  49. Wojcik SE, Rossi S, Shimizu M, Nicoloso MS, Cimmino A, Alder H, Herlea V, Rassenti LZ, Rai KR, Kipps TJ, Keating MJ, Croce CM, Calin GA. Non-codingRNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer. Carcinogenesis 2010; 31:208-15. PMID:19926640.
  50. Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJ, Padmanabhan S, Piotrowska M, Kozak T, Chan G, Davis R, Losic N, Wilms J, Russell CA, Osterborg A. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010; 28:1749-55. PMID:20194866.
  51. Wei J, Stebbins JL, Kitada S, Dash R, Placzek W, Rega MF, Wu B, Cellitti J, Zhai D, Yang L, Dahl R, Fisher PB, Reed JC, Pellecchia M. BI-97C1, an Optically Pure Apogossypol Derivative as Pan-Active Inhibitor of Antiapoptotic B-Cell Lymphoma/Leukemia-2 (Bcl-2) Family Proteins. J Med Chem 2010. PMID:20443627.
  52. Wang F, Ogasawara MA, Huang P. Small mitochondria-targeting molecules as anti-cancer agents. Mol Aspects Med 2010; 31:75-92. PMID:19995573.
  53. Volinia S, Visone R, Galasso M, Rossi E, Croce CM. Identification of microRNA activity by Targets' Reverse EXpression. Bioinformatics 2010; 26:91-7. PMID:19897564.
  54. Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, Marchesini J, Mascellani N, Sana ME, Abu Jarour R, Desponts C, Teitell M, Baffa R, Aqeilan R, Iorio MV, Taccioli C, Garzon R, Di Leva G, Fabbri M, Catozzi M, Previati M, Ambs S, Palumbo T, Garofalo M, Veronese A, Bottoni A, Gasparini P, Harris CC, Visone R, Pekarsky Y, de la Chapelle A, Bloomston M, Dillhoff M, Rassenti LZ, Kipps TJ, Huebner K, Pichiorri F, Lenze D, Cairo S, Buendia MA, Pineau P, Dejean A, Zanesi N, Rossi S, Calin GA, Liu CG, Palatini J, Negrini M, Vecchione A, Rosenberg A, Croce CM. Reprogramming of miRNA networks in cancer and leukemia. Genome Res 2010; 20:589-99. PMID:20439436.
  55. Valeri N, Gasparini P, Fabbri M, Braconi C, Veronese A, Lovat F, Adair B, Vannini I, Fanini F, Bottoni A, Costinean S, Sandhu SK, Nuovo GJ, Alder H, Gafa R, Calore F, Ferracin M, Lanza G, Volinia S, Negrini M, McIlhatton MA, Amadori D, Fishel R, Croce CM. Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci U S A 2010; 107:6982-7. PMID:20351277.
  56. Shustik C, Turner AR, Desjardins P, Fernandez L, Rubin S, Larratt L, Duncan AM, Rizi D, Sadura A, Shepherd L, Li D, Rassenti L, Kipps T. Oral fludarabine in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia 2010; 24:237-9. PMID:19812607.
  57. Shi R, Re D, Dudl E, Cuddy M, Okolotowicz KJ, Dahl R, Su Y, Hurder A, Kitada S, Peddibhotla S, Roth GP, Smith LH, Kipps TJ, Cosford N, Cashman J, Reed JC. Chemical Biology Strategy Reveals Pathway-Selective Inhibitor of NF-kappaB Activation Induced by Protein Kinase C. ACS Chem Biol 2010. PMID:20141195.
  58. Sanchez AB, Nguyen T, Dema-Ala R, Kummel AC, Kipps TJ, Messmer BT. A general process for the development of peptide-based immunoassays for monoclonal antibodies. Cancer Chemother Pharmacol 2010. PMID:20087593.
  59. Rossi S, Shimizu M, Barbarotto E, Nicoloso MS, Dimitri F, Sampath D, Fabbri M, Lerner S, Barron LL, Rassenti LZ, Jiang L, Xiao L, Hu J, Secchiero P, Zauli G, Volinia S, Negrini M, Wierda W, Kipps TJ, Plunkett W, Coombes KR, Abruzzo LV, Keating MJ, Calin GA. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood 2010. PMID:20393129.
  60. Ramsay AG, Gribben JG. The 3 Rs in CLL immune dysfunction. Blood 2010; 115:2563-4. PMID:20360474.
  61. Palamarchuk A, Efanov A, Nazaryan N, Santanam U, Alder H, Rassenti L, Kipps T, Croce CM, Pekarsky Y. 13q14 deletions in CLL involve cooperating tumor suppressors. Blood 2010. PMID:20071661.
  62. Liu X, Wang Y, Benaissa S, Matsuda A, Kantarjian H, Estrov Z, Plunkett W. Homologous recombination as a resisitance mechanism in replication-induced double-strand break caused by the anti-leukemia agent. Blood 2010; In Press. PMID
  63. Liu FT, Giustiniani J, Farren T, Jia L, Bensussan A, Gribben JG, Agrawal SG. CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia. Blood 2010; 115:3079-88. PMID:20164468.
  64. Lin TS, Blum KA, Fischer DB, Mitchell SM, Ruppert AS, Porcu P, Kraut EH, Baiocchi RA, Moran ME, Johnson AJ, Schaaf LJ, Grever MR, Byrd JC. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J Clin Oncol 2010; 28:418-23. PMID:20008633.
  65. Kipps TJ. Current Understanding of prognostic markers in chronic lymphocytic leukemia. In: K Stamatopoulos; P Ghia; R Rosenquist, editors New Biological Prognostic Markers in Chronic Lymphocytic Leukemia. 1 edn. Milan, Italy: Wolters Lewer Health, Ltd; 2010; p. 1-12.
  66. Kipps TJ. Functions of T lymphocytes: T-cell receptors for antigen. In: K Kaushanky; MA Lichtman; TJ Kipps; E Beutler; U Seligsohn; JT Prchal, editors Williams Hematology. New York: McGraw-Hill, Inc.; 2010; p. 1119-30.
  67. Kipps TJ. Classification and clinical manifestation of lymphocytes and plasma cell disorders. In: K Kaushanky; MA Lichtman; T Kipps; E Beutler; U Seligsohn; JT Prchal, editors Williams Hematology. New York: McGraw-Hill, Inc.; 2010.
  68. Kipps TJ. Functions of B lymphocytes and plasma cells in immunoglobulin production. In: K Kaushanky; MA Lichtman; TJ Kipps; E Beutler; U Seligsohn; JT Prchal, editors Williams Hematology. 8th edn. New York: McGraw-Hill, Inc.; 2010.
  69. Kipps TJ. Chronic Lymphocytic Leukemia and related diseases. In: K Kaushanky; MA Lichtman; TJ Kipps; E Beutler; U Seligsohn; JT Prchal, editors Williams Hematology. 8 edn. New York: McGraw-Hill, Inc.; 2010; p. 1431-82.
  70. Kipps TJ. The Cluster of Differentiation (CD) Antigens. In: K Kaushanky; MA Lichtman; E Beutler; TJ Kipps; U Seligsohn; JT Prchal, editors Williams Hematology. 8th edn. New York: McGraw-Hill, Inc.; 2010; p. 183-210.
  71. Hertlein E, Wagner AJ, Jones J, Lin TS, Maddocks KJ, Towns WH, 3rd, Goettl VM, Zhang X, Jarjoura D, Raymond CA, West DA, Croce CM, Byrd JC, Johnson AJ. 17-DMAG targets the NF-{kappa}B family of proteins to induce apoptosis in CLL: clinical implications of HSP90 inhibition. Blood 2010. PMID:20351313.
  72. Haferlach T, Kohlmann A, Wieczorek L, Basso G, Te Kronnie G, Bene MC, De Vos J, Hernandez JM, Hofmann WK, Mills KI, Gilkes A, Chiaretti S, Shurtleff SA, Kipps TJ, Rassenti LZ, Yeoh AE, Papenhausen PR, Liu WM, Williams PM, Foa R. Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Subclassification of Leukemia: Report From the International Microarray Innovations in Leukemia Study Group. J Clin Oncol 2010. PMID:20406941.
  73. Gribben JG. How I treat CLL up front. Blood 2010; 115:187-97. PMID:19850738.
  74. Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, Liu S, Schwind S, Santhanam R, Hickey CJ, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, Huettner CS, Bhatia R, Roy DC, Liebhaber SA, Caligiuri MA, Marcucci G, Garzon R, Croce CM, Calin GA, Perrotti D. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell 2010; 140:652-65. PMID:20211135.
  75. Efanov A, Zanesi N, Nazaryan N, Santanam U, Palamarchuk A, Croce CM, Pekarsky Y. CD5+CD23+ leukemic cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation. Leukemia 2010. PMID:20357824.
  76. Du S, Rashidi HH, Le DT, Kipps TJ, Broome HE, Wang HY. Systemic mastocytosis in association with chronic lymphocytic leukemia and plasma cell myeloma. Int J Clin Exp Pathol 2010; 3:448-57. PMID:20490336.
  77. Dennison JB, Ayres ML, Kaluarachchi K, Plunkett W, Gandhi V. Intracellular succinylation of 8-chloroadenosine and its effect on fumarate levels. J Biol Chem 2010; 285:8022-30. PMID:20064937.
  78. Clear AJ, Lee AM, Calaminici M, Ramsay AG, Morris KJ, Hallam S, Kelly G, Macdougall F, Lister TA, Gribben JG. Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163+ macrophages within the immediate sprouting micro-environment. Blood 2010. PMID:20375314.
  79. Cheson BD, Wendtner CM, Pieper A, Dreyling M, Friedberg J, Hoelzer D, Moreau P, Gribben J, Knop S, Montillo M, Rummel M. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 2010; 10:21-7. PMID:20223726.
  80. Chen R, Plunkett W. Strategy to induce apoptosis and circumvent resistance in chronic lymphocytic leukemia. Best Pract Res Clin Haematol 2010; In Press. PMID
  81. Byrd JC, Kipps TJ, Flinn IW, Castro J, Lin TS, Wierda W, Heerema N, Woodworth J, Hughes S, Tangri S, Harris S, Wynne D, Molina A, Leigh B, O'Brien S. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2010; 115:489-95. PMID:19843887.
  82. Butler T, Gribben JG. Biologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia. Blood Rev 2010; 24:135-41. PMID:20398985.
  83. Balakrishnan K, Verma D, O'Brien S, Kilpatrick JM, Chen Y, Tyler BF, Bickel S, Bantia S, Keating MJ, Kantarjian H, Gandhi V, Ravandi F. Phase II and pharmacodynamic study of oral forodesine in patients with advanced and/or fludarabine-treated chronic lymphocytic leukemia. Blood 2010. PMID:20427701.
  84. Awan FT, Johnson AJ, Lapalombella R, Hu W, Lucas M, Fischer B, Byrd JC. Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 2010; 51:27-38. PMID:20055657.
  85. Xiao W, Hong H, Kawakami Y, Kato Y, Wu D, Yasudo H, Kimura A, Kubagawa H, Bertoli LF, Davis RS, Chau LA, Madrenas J, Hsia CC, Xenocostas A, Kipps TJ, Hennighausen L, Iwama A, Nakauchi H, Kawakami T. Tumor suppression by phospholipase C-beta3 via SHP-1-mediated dephosphorylation of Stat5. Cancer Cell 2009; 16:161-71. PMID:19647226
  86. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller C, Burger J, Lerner S, Kantarjian H, Keating M. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol 2009; 27:1637-43. PMID:19224852.
  87. Wei J, Rega MF, Kitada S, Yuan H, Zhai D, Risbood P, Seltzman HH, Twine CE, Reed JC, Pellecchia M. Synthesis and evaluation of Apogossypol atropisomers as potential Bcl-xL antagonists. Cancer Lett 2009; 273:107-13. PMID:18782651.
  88. Wei J, Kitada S, Rega MF, Emdadi A, Yuan H, Cellitti J, Stebbins JL, Zhai D, Sun J, Yang L, Dahl R, Zhang Z, Wu B, Wang S, Reed TA, Wang HG, Lawrence N, Sebti S, Reed JC, Pellecchia M. Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins. Mol Cancer Ther 2009; 8:904-13. PMID:19372563.
  89. Visone R, Rassenti LZ, Veronese A, Taccioli C, Costinean S, Aguda BD, Volinia S, Ferracin M, Palatini J, Balatti V, Alder H, Negrini M, Kipps TJ, Croce CM. Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood 2009; 114:3872-9. PMID:19717645.
  90. Visone R, Croce CM. MiRNAs and cancer. Am J Pathol 2009; 174:1131-8. PMID:19264914.
  91. Tsai CY, Ray AS, Tumas DB, Keating MJ, Reiser H, Plunkett W. Targeting DNA repair in chronic lymphocytic leukemia cells with a novel acyclic nucleotide analogue, GS-9219. Clin Cancer Res 2009; 15:3760-9. PMID:19435836.
  92. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 2009; 8:579-91. PMID:19478820.
  93. Tili E, Croce CM, Michaille JJ. miR-155: on the crosstalk between inflammation and cancer. Int Rev Immunol 2009; 28:264-84. PMID:19811312.
  94. Su X, Lucas DM, Zhang L, Xu H, Zabrouskov V, Davis ME, Knapp AR, Young DC, Payne PR, Parthun MR, Marcucci G, Grever MR, Byrd JC, Freitas MA. Validation of an LC-MS based approach for profiling histones in chronic lymphocytic leukemia. Proteomics 2009; 9:1197-206. PMID:19253275.
  95. Steininger C, Rassenti LZ, Vanura K, Eigenberger K, Jager U, Kipps TJ, Mannhalter C, Stilgenbauer S, Popow-Kraupp T. Relative seroprevalence of human herpes viruses in patients with chronic lymphocytic leukaemia. Eur J Clin Invest 2009; 39:497-506. PMID:19490058.
  96. Spizzo R, Nicoloso MS, Croce CM, Calin GA. SnapShot: MicroRNAs in Cancer. Cell 2009; 137:586- e1. PMID:19410551.
  97. Spizzo R, Calin GA. Multiple approach to analyzing the role of microRNAs in apoptosis. Methods Mol Biol 2009; 559:219-45. PMID:19609760.
  98. Seiler T, Woelfle M, Yancopoulos S, Catera R, Li W, Hatzi K, Moreno C, Torres M, Paul S, Dohner H, Stilgenbauer S, Kaufman MS, Kolitz JE, Allen SL, Rai KR, Chu CC, Chiorazzi N. Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells. Blood 2009; 114:3615-24. PMID:19690339.
  99. Sampath D, Calin GA, Puduvalli VK, Gopisetty G, Taccioli C, Liu CG, Ewald B, Liu C, Keating MJ, Plunkett W. Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. Blood 2009; 113:3744-53. PMID:19096009.
  100. Rieger R, Whitacre D, Cantwell MJ, Prussak C, Kipps TJ. Chimeric form of tumor necrosis factor-alpha has enhanced surface expression and antitumor activity. Cancer Gene Ther 2009; 16:53-64. PMID:18654609.
  101. Riches JC, Gribben JG. Interesting times in the diagnosis and treatment of CLL. Oncology (Williston Park) 2009; 23:1043, 6. PMID:20017286.
  102. Ramsay AG, Gribben JG. Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug. Haematologica 2009; 94:1198-202. PMID:19734414.
  103. Ramsay AG, Clear AJ, Kelly G, Fatah R, Matthews J, Macdougall F, Lister TA, Lee AM, Calaminici M, Gribben JG. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood 2009; 114:4713-20. PMID:19786615.
  104. Ragone G, Bresin A, Piermarini F, Lazzeri C, Picchio MC, Remotti D, Kang SM, Cooper MD, Croce CM, Narducci MG, Russo G. The Tcl1 oncogene defines secondary hair germ cells differentiation at catagen-telogen transition and affects stem-cell marker CD34 expression. Oncogene 2009; 28:1329-38. PMID:19169282.
  105. Phelps MA, Lin TS, Johnson AJ, Hurh E, Rozewski DM, Farley KL, Wu D, Blum KA, Fischer B, Mitchell SM, Moran ME, Brooker-McEldowney M, Heerema NA, Jarjoura D, Schaaf LJ, Byrd JC, Grever MR, Dalton JT. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 2009; 113:2637-45. PMID:18981292.
  106. Pelicano H, Lu W, Zhou Y, Zhang W, Chen Z, Hu Y, Huang P. Mitochondrial dysfunction and reactive oxygen species imbalance promote breast cancer cell motility through a CXCL14-mediated mechanism. Cancer Res 2009; 69:2375-83. PMID:19276362.
  107. Payne PR, Embi PJ, Sen CK. Translational informatics: enabling high-throughput research paradigms. Physiol Genomics 2009; 39:131-40. PMID:19737991.
  108. O'Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ, Viallet J, Cheson BD. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 2009; 113:299-305. PMID:18931344.
  109. Nuovo GJ, Elton TS, Nana-Sinkam P, Volinia S, Croce CM, Schmittgen TD. A methodology for the combined in situ analyses of the precursor and mature forms of microRNAs and correlation with their putative targets. Nat Protoc 2009; 4:107-15. PMID:19131963.
  110. Messmer BT, Raphael BJ, Aerni SJ, Widhopf GF, Rassenti LZ, Gribben JG, Kay NE, Kipps TJ. Computational identification of CDR3 sequence archetypes among immunoglobulin sequences in chronic lymphocytic leukemia. Leuk Res 2009; 33:368-76. PMID:18640719.
  111. Lucas DM, Edwards RB, Lozanski G, West DA, Shin JD, Vargo MA, Davis ME, Rozewski DM, Johnson AJ, Su BN, Goettl VM, Heerema NA, Lin TS, Lehman A, Zhang X, Jarjoura D, Newman DJ, Byrd JC, Kinghorn AD, Grever MR. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood 2009; 113:4656-66. PMID:19190247.
  112. Lu D, Liu JX, Endo T, Zhou H, Yao S, Willert K, Schmidt-Wolf IG, Kipps TJ, Carson DA. Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/beta-catenin pathway. PLoS One 2009; 4:e8294. PMID:20011538.
  113. Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA, Blum KA, Flynn JM, Jones JA, Hu W, Moran ME, Mitchell SM, Smith LL, Wagner AJ, Raymond CA, Schaaf LJ, Phelps MA, Villalona-Calero MA, Grever MR, Byrd JC. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 2009; 27:6012-8. PMID:19826119.
  114. Lin KI, Tam CS, Keating MJ, Wierda WG, O'Brien S, Lerner S, Coombes KR, Schlette E, Ferrajoli A, Barron LL, Kipps TJ, Rassenti L, Faderl S, Kantarjian H, Abruzzo LV. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood 2009; 113:3168-71. PMID:19050308.
  115. Le Dieu R, Taussig DC, Ramsay AG, Mitter R, Miraki-Moud F, Fatah R, Lee AM, Lister TA, Gribben JG. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood 2009; 114:3909-16. PMID:19710498.
  116. Le Dieu R, Taussig D, Lister TA, Gribben JG. Negative immunomagnetic selection of T cells from peripheral blood of presentation AML specimens. J Immunol Methods 2009; 348:95-100. PMID:19576900.
  117. Lapalombella R, Gowda A, Joshi T, Mehter N, Cheney C, Lehman A, Chen CS, Johnson AJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC. The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia. Br J Haematol 2009; 144:848-55. PMID:19183192.
  118. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 2009; 27:5848-56. PMID:19884536.
  119. Hallam S, Gribben JG. Transplantation in chronic lymphocytic leukemia: timing and expectations. Clin Lymphoma Myeloma 2009; 9 Suppl 3:S186-93. PMID:19778839.
  120. Gribben JG, Hallek M. Rediscovering alemtuzumab: current and emerging therapeutic roles. Br J Haematol 2009; 144:818-31. PMID:19183194.
  121. Gribben JG. One step back but 2 steps forward. Blood 2009; 114:3359-60. PMID:19833846.
  122. Gribben JG. Stem cell transplantation in chronic lymphocytic leukemia. Biol Blood Marrow Transplant 2009; 15:53-8. PMID:19147079.
  123. Gorgun G, Ramsay AG, Holderried TA, Zahrieh D, Le Dieu R, Liu F, uackenbush J, Croce CM, Gribben JG. E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci U S A 2009; 106:6250-5. PMID:19332800.
  124. Ghosh AK, Shanafelt TD, Cimmino A, Taccioli C, Volinia S, Liu CG, Calin GA, Croce CM, Chan DA, Giaccia AJ, Secreto C, Wellik LE, Lee YK, Mukhopadhyay D, Kay NE. Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. Blood 2009; 113:5568-74. PMID:19336759.
  125. Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. Annu Rev Med 2009; 60:167-79. PMID:19630570.
  126. Enzler T, Kater AP, Zhang W, Widhopf GF, 2nd, CHuang HY, Lee J, Avery E, Croce CM, Karin M, Kipps TJ. Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression. Blood 2009; 114:4469-76. PMID:19755673.
  127. Embi PJ, Payne PR. Clinical research informatics: challenges, opportunities and definition for an emerging domain. J Am Med Inform Assoc 2009; 16:316-27. PMID:19261934.
  128. Embi PJ, Kaufman SE, Payne PR. Biomedical informatics and outcomes research: enabling knowledge-driven health care. Circulation 2009; 120:2393-9. PMID:19996023.
  129. Elter T, Vehreschild JJ, Gribben J, Cornely OA, Engert A, Hallek M. Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. Ann Hematol 2009; 88:121-32. PMID:18682948.
  130. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009; 10:704-14. PMID:19763153.
  131. Costinean S, Sandhu SK, Pedersen IM, Tili E, Trotta R, Perrotti D, Ciarlariello D, Neviani P, Harb J, Kauffman LR, Shidham A, Croce CM. Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice. Blood 2009; 114:1374-82. PMID:19520806.
  132. Chen SS, Sherman MH, Hertlein E, Johnson AJ, Teitell MA, Byrd JC, Plass C. Epigenetic alterations in a murine model for chronic lymphocytic leukemia. Cell Cycle 2009; 8:3663-7. PMID:19901553.
  133. Chen SS, Raval A, Johnson AJ, Hertlein E, Liu TH, Jin VX, Sherman MH, Liu SJ, Dawson DW, Williams KE, Lanasa M, Liyanarachchi S, Lin TS, Marcucci G, Pekarsky Y, Davuluri R, Croce CM, Guttridge DC, Teitell MA, Byrd JC, Plass C. Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2009; 106:13433-8. PMID:19666576.
  134. Chen R, Wierda WG, Chubb S, Hawtin RE, Fox JA, Keating MJ, Gandhi V, Plunkett W. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 2009; 113:4637-45. PMID:19234140.
  135. Chen LS, Redkar S, Bearss D, Wierda WG, Gandhi V. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2009; 114:4150-7. PMID:19734450.89.            Castro JE, James DF, Sandoval-Sus JD, Jain S, Bole J, Rassenti L, Kipps TJ. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia 2009; 23:1779-89. PMID:19693094.
  136. Calin GA, Croce CM. Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes. Blood 2009; 114:4761-70. PMID:19745066.
  137. Buhl AM, Novotny GW, Josefsson P, Nielsen JE, Pedersen LB, Geisler C, Rassenti LZ, Kipps TJ, Jurlander J, Leffers H. The CLLU1 expression level is a stable and inherent feature of the chronic lymphocytic leukemia clone. Leukemia 2009; 23:1182-6. PMID:19212335.
  138. Balakrishnan K, Burger JA, Wierda WG, Gandhi V. AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood 2009; 113:149-53. PMID:18836097.
  139. Awan FT, Kay NE, Davis ME, Wu W, Geyer SM, Leung N, Jelinek DF, Tschumper RC, Secreto CR, Lin TS, Grever MR, Shanafelt TD, Zent CS, Call TG, Heerema NA, Lozanski G, Byrd JC, Lucas DM. Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. Blood 2009; 113:535-7. PMID:19008456.
  140. Zhao X, Wu J, Muthusamy N, Byrd JC, Lee RJ. Liposomal coencapsulated fludarabine and mitoxantrone for lymphoproliferative disorder treatment. J Pharm Sci 2008; 97:1508-18. PMID:17722102.
  141. Zhang L, Murray F, Zahno A, Kanter JR, Chou D, Suda R, Fenlon M, Rassenti L, Cottam H, Kipps TJ, Insel PA. Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2008; 105:19532-7. PMID:19033455.
  142. Zhang H, Trachootham D, Lu W, Carew J, Giles FJ, Keating MJ, Arlinghaus RB, Huang P. Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia 2008; 22:1191-9. PMID:18385754.
  143. Widhopf GF, 2nd, Goldberg CJ, Toy TL, Rassenti LZ, Wierda WG, Byrd JC, Keating MJ, Gribben JG, Rai KR, Kipps TJ. Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3. Blood 2008; 111:3137-44. PMID:17675554.
  144. Volinia S, Mascellani N, Marchesini J, Veronese A, Ormondroyd E, Alder H, Palatini J, Negrini M, Croce CM. Genome wide identification of recessive cancer genes by combinatorial mutation analysis. PLoS One 2008; 3:e3380. PMID:18846217.
  145. Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2008; 26:196-203. PMID:18182662.
  146. Trachootham D, Zhang H, Zhang W, Feng L, Du M, Zhou Y, Chen Z, Pelicano H, Plunkett W, Wierda WG, Keating MJ, Huang P. Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood 2008; 112:1912-22. PMID:18574029.
  147. Taussig DC, Miraki-Moud F, Anjos-Afonso F, Pearce DJ, Allen K, Ridler C, Lillington D, Oakervee H, Cavenagh J, Agrawal SG, Lister TA, Gribben JG, Bonnet D. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 2008; 112:568-75. PMID:18523
  148. Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA, Thomas DA, Cortes J, Lerner S, Keating MJ. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112:975-80. PMID:18411418.
  149. Rassenti LZ, Jain S, Keating MJ, Wierda WG, Grever MR, Byrd JC, Kay NE, Brown JR, Gribben JG, Neuberg DS, He F, Greaves AW, Rai KR, Kipps TJ. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 2008; 112:1923-30. PMID:18577710.
  150. Rao M, Casimiro MC, Lisanti MP, D'Amico M, Wang C, Shirley LA, Leader JE, Liu M, Stallcup M, Engel DA, Murphy DJ, Pestell RG. Inhibition of cyclin D1 gene transcription by Brg-1. Cell Cycle 2008; 7:647-55. PMID:18239461.
  151. Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W, Byrd JC, Gribben JG. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008; 118:2427-37. PMID:18551193.
  152. Prueitt RL, Yi M, Hudson RS, Wallace TA, Howe TM, Yfantis HG, Lee DH, Stephens RM, Liu CG, Calin GA, Croce CM, Ambs S. Expression of microRNAs and protein-coding genes associated with perineural invasion in prostate cancer. Prostate 2008; 68:1152-64. PMID:18459106.
  153. Proto-Siqueira R, Panepucci RA, Careta FP, Lee A, Clear A, Morris K, Owen C, Rizzatti EG, Silva WA, Jr., Falcao RP, Zago MA, Gribben JG. SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL. Blood 2008; 112:394-7. PMID:18434611.
  154. Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D, Taccioli C, Zanesi N, Alder H, Hagan JP, Munker R, Volinia S, Boccadoro M, Garzon R, Palumbo A, Aqeilan RI, Croce CM. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A 2008; 105:12885-90. PMID:18728182.
  155. Phelps MA, Rozewski DM, Johnston JS, Farley KL, Albanese KA, Byrd JC, Lin TS, Grever MR, Dalton JT. Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 868:110-5. PMID:18490204.
  156. Pekarsky Y, Palamarchuk A, Maximov V, Efanov A, Nazaryan N, Santanam U, Rassenti L, Kipps T, Croce CM. Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. Proc Natl Acad Sci U S A 2008; 105:19643-8. PMID:19064921.
  157. Payne PR, Kwok A, Greaves AW. Integrating web portlet technologies with caGrid to enable rapid application development: the CRC Patient Study Calendar. AMIA Annu Symp Proc 2008:1087. PMID:18998940.
  158. Payne PR, Borlawsky TB, Kwok A, Greaves AW. Supporting the design of translational clinical studies through the generation and verification of conceptual knowledge-anchored hypotheses. AMIA Annu Symp Proc 2008:566-70. PMID:18998958.
  159. O'Shea D, O'Riain C, Taylor C, Waters R, Carlotti E, Macdougall F, Gribben J, Rosenwald A, Ott G, Rimsza LM, Smeland EB, Johnson N, Campo E, Greiner TC, Chan WC, Gascoyne RD, Wright G, Staudt LM, Lister TA, Fitzgibbon J. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood 2008; 112:3126-9. PMID:18628487.
  160. Liu Q, Zhao X, Frissora F, Ma Y, Santhanam R, Jarjoura D, Lehman A, Perrotti D, Chen CS, Dalton JT, Muthusamy N, Byrd JC. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood 2008; 111:275-84. PMID:17761520.
  161. Liu Q, Farley KL, Johnson AJ, Muthusamy N, Hofmeister CC, Blum KA, Schaaf LJ, Grever MR, Byrd JC, Dalton JT, Phelps MA. Development and Validation of a Highly Sensitive Liquid Chromatography/Mass Spectrometry Method for Simultaneous Quantification of Lenalidomide and Flavopiridol in Human Plasma. Ther Drug Monit 2008. PMID:18708993.
  162. Liu FT, Agrawal SG, Movasaghi Z, Wyatt PB, Rehman IU, Gribben JG, Newland AC, Jia L. Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib. Blood 2008; 112:3835-46. PMID:18633129.
  163. Liu FT, Agrawal SG, Gribben JG, Ye H, Du MQ, Newland AC, Jia L. Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL. Blood 2008; 111:2797-805. PMID:18160669.
  164. Liu CG, Spizzo R, Calin GA, Croce CM. Expression profiling of microRNA using oligo DNA arrays. Methods 2008; 44:22-30. PMID:18158129.
  165. Liu CG, Calin GA, Volinia S, Croce CM. MicroRNA expression profiling using microarrays. Nat Protoc 2008; 3:563-78. PMID:18388938.
  166. Lapalombella R, Zhao X, Triantafillou G, Yu B, Jin Y, Lozanski G, Cheney C, Heerema N, Jarjoura D, Lehman A, Lee LJ, Marcucci G, Lee RJ, Caligiuri MA, Muthusamy N, Byrd JC. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents. Clin Cancer Res 2008; 14:569-78. PMID:18223233.
  167. Lapalombella R, Yu B, Triantafillou G, Liu Q, Butchar JP, Lozanski G, Ramanunni A, Smith LL, Blum W, Andritsos L, Wang DS, Lehman A, Chen CS, Johnson AJ, Marcucci G, Lee RJ, Lee LJ, Tridandapani S, Muthusamy N, Byrd JC. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood 2008; 112:5180-9. PMID:18772452.
  168. Kohlmann A, Kipps TJ, Rassenti LZ, Downing JR, Shurtleff SA, Mills KI, Gilkes AF, Hofmann WK, Basso G, Dell'orto MC, Foa R, Chiaretti S, De Vos J, Rauhut S, Papenhausen PR, Hernandez JM, Lumbreras E, Yeoh AE, Koay ES, Li R, Liu WM, Williams PM, Wieczorek L, Haferlach T. An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase. Br J Haematol 2008; 142:802-7. PMID:18573112.
  169. Kitada S, Kress CL, Krajewska M, Jia L, Pellecchia M, Reed JC. Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048). Blood 2008; 111:3211-9. PMID:18202226.
  170. Kipps TJ. Genomic complexity in chronic lymphocytic leukemia. Blood 2008; 112:1550. PMID:18725569.
  171. Kamal J, Silvey SA, Buskirk J, Ostrander M, Erdal S, Dhaval R, Ding J, Borlawsky T, Smaltz DH, Payne PR. Innovative applications of an enterprise-wide information warehouse. AMIA Annu Symp Proc 2008:1134. PMID:18999273.
  172. Jia L, Coward LC, Kerstner-Wood CD, Cork RL, Gorman GS, Noker PE, Kitada S, Pellecchia M, Reed JC. Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate. Cancer Chemother Pharmacol 2008; 61:63-73. PMID:17356822.
  173. Hussain SR, Lucas DM, Johnson AJ, Lin TS, Bakaletz AP, Dang VX, Viatchenko-Karpinski S, Ruppert AS, Byrd JC, Kuppusamy P, Crouser ED, Grever MR. Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium. Blood 2008; 111:3190-9. PMID:18192508.
  174. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111:5446-56. PMID:18216293.
  175. Gribben JG. Molecular profiling in CLL. Hematology Am Soc Hematol Educ Program 2008:444-9. PMID:19074124.
  176. Gribben JG. Role of allogeneic hematopoietic stem-cell transplantation in chronic lymphocytic leukemia. J Clin Oncol 2008; 26:4864-5. PMID:18794537.
  177. Gribben JG. New agents in chronic lymphocytic leukemia. Clin Adv Hematol Oncol 2008; 6:409-10, 68. PMID:18567984.
  178. Gilleece MH, Pearce R, Linch DC, Wilson M, Towlson K, Mackinnon S, Potter M, Kazmi M, Gribben JG, Marks DI. The outcome of haemopoietic stem cell transplantation in the treatment of lymphoplasmacytic lymphoma in the UK: a British Society Bone Marrow Transplantation study. Hematology 2008; 13:119-27. PMID:18616880.
  179. Ghia EM, Jain S, Widhopf GF, 2nd, Rassenti LZ, Keating MJ, Wierda WG, Gribben JG, Brown JR, Rai KR, Byrd JC, Kay NE, Greaves AW, Kipps TJ. Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. Blood 2008; 111:5101-8. PMID:18326815.
  180. Garzon R, Croce CM. MicroRNAs in normal and malignant hematopoiesis. Curr Opin Hematol 2008; 15:352-8. PMID:18536574.
  181. Gandhi V, Tam C, O'Brien S, Jewell RC, Rodriguez CO, Jr., Lerner S, Plunkett W, Keating MJ. Phase I trial of nelarabine in indolent leukemias. J Clin Oncol 2008; 26:1098-105. PMID:18309944.
  182. Gandhi V, Balakrishnan K, Chen LS. Mcl-1: the 1 in CLL. Blood 2008; 112:3538-40. PMID:18948586.
  183. Fukuda T, Chen L, Endo T, Tang L, Lu D, Castro JE, Widhopf GF, 2nd, Rassenti LZ, Cantwell MJ, Prussak CE, Carson DA, Kipps TJ. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci U S A 2008; 105:3047-52. PMID:18287027.
  184. Fiorenza MT, Torcia S, Canterini S, Bevilacqua A, Narducci MG, Ragone G, Croce CM, Russo G, Mangia F. TCL1 promotes blastomere proliferation through nuclear transfer, but not direct phosphorylation, of AKT/PKB in early mouse embryos. Cell Death Differ 2008; 15:420-2. PMID:17901877.
  185. Ewald B, Sampath D, Plunkett W. Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene 2008; 27:6522-37. PMID:18955977.
  186. Demizu Y, Sasaki R, Trachootham D, Pelicano H, Colacino JA, Liu J, Huang P. Alterations of cellular redox state during NNK-induced malignant transformation and resistance to radiation. Antioxid Redox Signal 2008; 10:951-61. PMID:18257743.
  187. de Yebenes VG, Belver L, Pisano DG, Gonzalez S, Villasante A, Croce C, He L, Ramiro AR. miR-181b negatively regulates activation-induced cytidine deaminase in B cells. J Exp Med 2008; 205:2199-206. PMID:18762567.
  188. Davies JK, Gribben JG, Brennan LL, Yuk D, Nadler LM, Guinan EC. Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies. Blood 2008; 112:2232-41. PMID:18617635.
  189. Croce CM. MicroRNAs and lymphomas. Ann Oncol 2008; 19 Suppl 4:iv39-40. PMID:18519400.
  190. Croce CM. Oncogenes and cancer. N Engl J Med 2008; 358:502-11. PMID:18234754.       
  191. Cillessen SA, Reed JC, Welsh K, Pinilla C, Houghten R, Hooijberg E, Deurhof J, Castricum KC, Kortman P, Hess CJ, Ossenkoppele GJ, Meijer CJ, Oudejans JJ. Small-molecule XIAP antagonist restores caspase-9 mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells. Blood 2008; 111:369-75. PMID:17916749.
  192. Chen L, Huynh L, Apgar J, Tang L, Rassenti L, Weiss A, Kipps TJ. ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood 2008; 111:2685-92. PMID:18048647.
  193. Castro JE, Sandoval-Sus JD, Bole J, Rassenti L, Kipps TJ. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 2008; 22:2048-53. PMID:18754025.
  194. Calin GA, Cimmino A, Fabbri M, Ferracin M, Wojcik SE, Shimizu M, Taccioli C, Zanesi N, Garzon R, Aqeilan RI, Alder H, Volinia S, Rassenti L, Liu X, Liu CG, Kipps TJ, Negrini M, Croce CM. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A 2008; 105:5166-71. PMID:18362358.
  195. Borlawsky T, LaFountain J, Petty L, Saltz JH, Payne PR. Leveraging an existing data warehouse to annotate workflow models for operations research and optimization. AMIA Annu Symp Proc 2008:885. PMID:18999220.
  196. Balakrishnan K, Wierda WG, Keating MJ, Gandhi V. Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2008; 112:1971-80. PMID:18566329.
  197. Andritsos LA, Johnson AJ, Lozanski G, Blum W, Kefauver C, Awan F, Smith LL, Lapalombella R, May SE, Raymond CA, Wang DS, Knight RD, Ruppert AS, Lehman A, Jarjoura D, Chen CS, Byrd JC. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 2008; 26:2519-25. PMID:18427150.
  198. Agrawal SG, Liu FT, Wiseman C, Shirali S, Liu H, Lillington D, Du MQ, Syndercombe-Court D, Newland AC, Gribben JG, Jia L. Increased proteasomal degradation of Bax is a common feature of poor prognosis chronic lymphocytic leukemia. Blood 2008; 111:2790-6. PMID:18160666.
  199. Zhao X, Lapalombella R, Joshi T, Cheney C, Gowda A, Hayden-Ledbetter MS, Baum PR, Lin TS, Jarjoura D, Lehman A, Kussewitt D, Lee RJ, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 2007; 110:2569-77. PMID:17440052.
  200. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Cortes J, Thomas D, Garcia-Manero G, Koller C, Beran M, Giles F, Ravandi F, Lerner S, Kantarjian H, Keating M. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 2007; 109:4679-85. PMID:17299097.
  201. Wierda WG, Kipps TJ. Gene therapy and active immune therapy of hematologic malignancies. Best Pract Res Clin Haematol 2007; 20:557-68. PMID:17707840.
  202. Tsimberidou AM, Wen S, O'Brien S, McLaughlin P, Wierda WG, Ferrajoli A, Faderl S, Manning J, Lerner S, Mai CV, Rodriguez AM, Hess M, Do KA, Freireich EJ, Kantarjian HM, Medeiros LJ, Keating MJ. Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2007; 25:4648-56. PMID:17925562.
  203. Shanafelt TD, Lin T, Geyer SM, Zent CS, Leung N, Kabat B, Bowen D, Grever MR, Byrd JC, Kay NE. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer 2007; 109:2291-8. PMID:17514743.
  204. Sevignani C, Calin GA, Nnadi SC, Shimizu M, Davuluri RV, Hyslop T, Demant P, Croce CM, Siracusa LD. MicroRNA genes are frequently located near mouse cancer susceptibility loci. Proc Natl Acad Sci U S A 2007; 104:8017-22. PMID:17470785.
  205. Sellick GS, Goldin LR, Wild RW, Slager SL, Ressenti L, Strom SS, Dyer MJ, Mauro FR, Marti GE, Fuller S, Lyttelton M, Kipps TJ, Keating MJ, Call TG, Catovsky D, Caporaso N, Houlston RS. A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia. Blood 2007; 110:3326-33. PMID:17687107.
  206. Sampath D, Plunkett W. The role of DNA repair in chronic lymphocytic leukemia pathogenesis and chemotherapy resistance. Curr Oncol Rep 2007; 9:361-7. PMID:17706164.
  207. Rawstron AC, Villamor N, Ritgen M, Bottcher S, Ghia P, Zehnder JL, Lozanski G, Colomer D, Moreno C, Geuna M, Evans PA, Natkunam Y, Coutre SE, Avery ED, Rassenti LZ, Kipps TJ, Caligaris-Cappio F, Kneba M, Byrd JC, Hallek MJ, Montserrat E, Hillmen P. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007; 21:956-64. PMID:17361231.
  208. Raval A, Tanner SM, Byrd JC, Angerman EB, Perko JD, Chen SS, Hackanson B, Grever MR, Lucas DM, Matkovic JJ, Lin TS, Kipps TJ, Murray F, WeisenBurger D, Sanger W, Lynch J, Watson P, Jansen M, Yoshinaga Y, Rosenquist R, de Jong PJ, Coggill P, Beck S, Lynch H, de la Chapelle A, Plass C. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell 2007; 129:879-90. PMID:17540169.
  209. Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, David M. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 2007; 449:919-22. PMID:17943132.
  210. Payne PR, Mendonca EA, Starren JB. Modeling participant-related clinical research events using conceptual knowledge acquisition techniques. AMIA Annu Symp Proc 2007:593-7. PMID:18693905.
  211. Nicoloso MS, Kipps TJ, Croce CM, Calin GA. MicroRNAs in the pathogeny of chronic lymphocytic leukaemia. Br J Haematol 2007; 139:709-16. PMID:18021085.
  212. Negrini M, Ferracin M, Sabbioni S, Croce CM. MicroRNAs in human cancer: from research to therapy. J Cell Sci 2007; 120:1833-40. PMID:17515481.
  213. Nakamura T, Canaani E, Croce CM. Oncogenic All1 fusion proteins target Drosha-mediated microRNA processing. Proc Natl Acad Sci U S A 2007; 104:10980-5. PMID:17581865.
  214. Le Dieu R, Gribben JG. Transplantation in chronic lymphocytic leukemia. Curr Hematol Malig Rep 2007; 2:56-63. PMID:20425389.
  215. Kress CL, Konopleva M, Martinez-Garcia V, Krajewska M, Lefebvre S, Hyer ML, McQueen T, Andreeff M, Reed JC, Zapata JM. Triterpenoids display single agent anti-tumor activity in a transgenic mouse model of chronic lymphocytic leukemia and small B cell lymphoma. PLoS One 2007; 2:e559. PMID:17593960.
  216. Kipps TJ. Value of computed tomography in the monitoring of patients with chronic lymphocytic leukemia. J Clin Oncol 2007; 25:5556. PMID:17984183.
  217. Kipps TJ. The B-cell receptor and ZAP-70 in chronic lymphocytic leukemia. Best Pract Res Clin Haematol 2007; 20:415-24. PMID:17707830.
  218. Kay NE, Geyer SM, Call TG, Shanafelt TD, Zent CS, Jelinek DF, Tschumper R, Bone ND, Dewald GW, Lin TS, Heerema NA, Smith L, Grever MR, Byrd JC. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007; 109:405-11. PMID:17008537.
  219. Kato K, Chu P, Takahashi S, Hamada H, Kipps TJ. Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells. Exp Hematol 2007; 35:434-42. PMID:17309824.
  220. Kater AP, van Oers MH, Kipps TJ. Cellular immune therapy for chronic lymphocytic leukemia. Blood 2007; 110:2811-8. PMID:17638850.
  221. Kamal J, Borlawsky T, Payne PR. Development of an ontology-anchored data warehouse meta-model. AMIA Annu Symp Proc 2007:1001. PMID:18694100.
  222. Johnson AJ, Wagner AJ, Cheney CM, Smith LL, Lucas DM, Guster SK, Grever MR, Lin TS, Byrd JC. Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia. Br J Haematol 2007; 139:837-44. PMID:17949452.
  223. James DF, Kipps TJ. Alemtuzumab in chronic lymphocytic leukemia. Future Oncol 2007; 3:29-42. PMID:17280499.
  224. ITse T, Nagata S, Kreitman RJ, Wilson WH, Wayne AS, Stetler-Stevenson M, Bishop MR, Scheinberg DA, Rassenti L, Kipps TJ, Kyle RA, Jelinek DF, Pastan I. Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma. Leukemia 2007; 21:169-74. PMID:17051241.
  225. Hussain SR, Cheney CM, Johnson AJ, Lin TS, Grever MR, Caligiuri MA, Lucas DM, Byrd JC. Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin Cancer Res 2007; 13:2144-50. PMID:17404098.
  226. Gribben JG. Stem-cell transplantation in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 2007; 20:513-27. PMID:17707837.
  227. Gribben JG. How I treat indolent lymphoma. Blood 2007; 109:4617-26. PMID:17311989.
  228. Grever MR, Lucas DM, Johnson AJ, Byrd JC. Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia. Best Pract Res Clin Haematol 2007; 20:545-56. PMID:17707839.
  229. Grever MR, Lucas DM, Dewald GW, Neuberg DS, Reed JC, Kitada S, Flinn IW, Tallman MS, Appelbaum FR, Larson RA, Paietta E, Jelinek DF, Gribben JG, Byrd JC. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007; 25:799-804. PMID:17283363.
  230. Georgantas RW, 3rd, Hildreth R, Morisot S, Alder J, Liu CG, Heimfeld S, Calin GA, Croce CM, Civin CI. CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc Natl Acad Sci U S A 2007; 104:2750-5. PMID:17293455.
  231. Gandhi V, Balakrishnan K. Pharmacology and mechanism of action of forodesine, a T-cell targeted agent. Semin Oncol 2007; 34:S8-12. PMID:18086347.
  232. Gandhi V. p53 as a predictor for chemotherapy response in CLL cells. Leuk Lymphoma 2007; 48:219-20. PMID:17325877.
  233. Endo T, Nishio M, Enzler T, Cottam HB, Fukuda T, James DF, Karin M, Kipps TJ. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. Blood 2007; 109:703-10. PMID:16973958.
  234. Chiorazzi N. Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B cells. Best Pract Res Clin Haematol 2007; 20:399-413. PMID:17707829.
  235. Calin GA, Liu CG, Ferracin M, Hyslop T, Spizzo R, Sevignani C, Fabbri M, Cimmino A, Lee EJ, Wojcik SE, Shimizu M, Tili E, Rossi S, Taccioli C, Pichiorri F, Liu X, Zupo S, Herlea V, Gramantieri L, Lanza G, Alder H, Rassenti L, Volinia S, Schmittgen TD, Kipps TJ, Negrini M, Croce CM. Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell 2007; 12:215-29. PMID:17785203.
  236. Calin GA, Croce CM. Investigation of microRNA alterations in leukemias and lymphomas. Methods Enzymol 2007; 427:193-213. PMID:17720486.
  237. Calin GA, Croce CM. Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications. J Clin Invest 2007; 117:2059-66. PMID:17671640.
  238. Byrd JC, O'Brien S, Flinn IW, Kipps TJ, Weiss M, Rai K, Lin TS, Woodworth J, Wynne D, Reid J, Molina A, Leigh B, Harris S. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 2007; 13:4448-55. PMID:17671129.
  239. Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, Moran M, Blum KA, Rovin B, Brooker-McEldowney M, Broering S, Schaaf LJ, Johnson AJ, Lucas DM, Heerema NA, Lozanski G, Young DC, Suarez JR, Colevas AD, Grever MR. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007; 109:399-404. PMID:17003373.
  240. Browning RL, Geyer SM, Johnson AJ, Jelinek DF, Tschumper RC, Call TG, Shanafelt TD, Zent CS, Bone ND, Dewald GW, Lin TS, Heerema NA, Grever MR, Kay NE, Byrd JC, Lucas DM. Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia. Leuk Res 2007; 31:1737-40. PMID:17659340.
  241. Bowen DA, Call TG, Jenkins GD, Zent CS, Schwager SM, Van Dyke DL, Jelinek DF, Kay NE, Shanafelt TD. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma 2007; 48:2412-7. PMID:18067017.
  242. Borlawsky T, Payne PR. Evaluating an NLP-based approach to modeling computable clinical trial eligibility criteria. AMIA Annu Symp Proc 2007:878. PMID:18693979.
  243. Auer RL, Gribben J, Cotter FE. Emerging therapy for chronic lymphocytic leukaemia. Br J Haematol 2007; 139:635-44. PMID:17961187.
  244. Alexandre J, Hu Y, Lu W, Pelicano H, Huang P. Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. Cancer Res 2007; 67:3512-7. PMID:17440056.
  245. Zirlik KM, Zahrieh D, Neuberg D, Gribben JG. Cytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide. Blood 2006; 108:3865-70. PMID:16902144.
  246. Zanesi N, Aqeilan R, Drusco A, Kaou M, Sevignani C, Costinean S, Bortesi L, La Rocca G, Koldovsky P, Volinia S, Mancini R, Calin G, Scott CP, Pekarsky Y, Croce CM. Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice. Cancer Res 2006; 66:915-20. PMID:16424025.
  247. Yan XJ, Albesiano E, Zanesi N, Yancopoulos S, Sawyer A, Romano E, Petlickovski A, Efremov DG, Croce CM, Chiorazzi N. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2006; 103:11713-8. PMID:16864779.
  248. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, Chiao PJ, Achanta G, Arlinghaus RB, Liu J, Huang P. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 2006; 10:241-52. PMID:16959615.
  249. Sampath D, Cortes J, Estrov Z, Du M, Shi Z, Andreeff M, Gandhi V, Plunkett W. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 2006; 107:2517-24. PMID:16293603.
  250. Rassenti LZ, Kipps TJ. Clinical utility of assessing ZAP-70 and CD38 in chronic lymphocytic leukemia. Cytometry B Clin Cytom 2006; 70:209-13. PMID:16906583.
  251. Pelicano H, Xu RH, Du M, Feng L, Sasaki R, Carew JS, Hu Y, Ramdas L, Hu L, Keating MJ, Zhang W, Plunkett W, Huang P. Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol 2006; 175:913-23. PMID:17158952.
  252. Pelicano H, Carew JS, McQueen TJ, Andreeff M, Plunkett W, Keating MJ, Huang P. Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C. Leukemia 2006; 20:610-9. PMID:16482209.
  253. Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V, Volinia S, Alder H, Liu CG, Rassenti L, Calin GA, Hagan JP, Kipps T, Croce CM. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 2006; 66:11590-3. PMID:17178851.
  254. Moufarij MA, Sampath D, Keating MJ, Plunkett W. Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal. Blood 2006; 108:4187-93. PMID:16954499.
  255. Le Dieu R, Gribben J. Vaccine- and immune-based therapy in chronic lymphocytic leukemia. Semin Oncol 2006; 33:220-9. PMID:16616069.
  256. Johnson AJ, Lucas DM, Muthusamy N, Smith LL, Edwards RB, De Lay MD, Croce CM, Grever MR, Byrd JC. Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood 2006; 108:1334-8. PMID:16670263.
  257. Ghiotto F, Fais F, Albesiano E, Sison C, Valetto A, Gaidano G, Reinhardt J, Kolitz JE, Rai K, Allen SL, Ferrarini M, Chiorazzi N. Similarities and differences between the light and heavy chain Ig variable region gene repertoires in chronic lymphocytic leukemia. Mol Med 2006; 12:300-8. PMID:17380195.
  258. Garzon R, Fabbri M, Cimmino A, Calin GA, Croce CM. MicroRNA expression and function in cancer. Trends Mol Med 2006; 12:580-7. PMID:17071139.
  259. Gandhi V, Plunkett W, Bonate PL, Du M, Nowak B, Lerner S, Keating MJ. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment. Clin Cancer Res 2006; 12:4011-7. PMID:16818700.
  260. Gandhi V, Plunkett W. Clofarabine and nelarabine: two new purine nucleoside analogs. Curr Opin Oncol 2006; 18:584-90. PMID:16988579.
  261. Gandhi V, Keating MJ, Bate G, Kirkpatrick P. Nelarabine. Nat Rev Drug Discov 2006; 5:17-8. PMID:16485343.
  262. Faderl S, Rai K, Gribben J, Byrd JC, Flinn IW, O'Brien S, Sheng S, Esseltine DL, Keating MJ. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. Cancer 2006; 107:916-24. PMID:16832816.
  263. Dicker F, Kater AP, Prada CE, Fukuda T, Castro JE, Sun G, Wang JY, Kipps TJ. CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53. Blood 2006; 108:3450-7. PMID:16741250.
  264. Coward L, Gorman G, Noker P, Kerstner-Wood C, Pellecchia M, Reed JC, Jia L. Quantitative determination of apogossypol, a pro-apoptotic analog of gossypol, in mouse plasma using LC/MS/MS. J Pharm Biomed Anal 2006; 42:581-6. PMID:16859853.
  265. Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N, Croce CM. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A 2006; 103:7024-9. PMID:16641092.
  266. Chiorazzi N, Ferrarini M. Evolving view of the in-vivo kinetics of chronic lymphocytic leukemia B cells. Hematology Am Soc Hematol Educ Program 2006:273-8, 512. PMID:17124072.
  267. Chen R, Gandhi V, Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res 2006; 66:10959-66. PMID:17108134.
  268. Castro JE, Prada CE, Aguillon RA, Kitada S, Fukuda T, Motta M, Wu C, Dicker F, Sun G, Wang JY, Carson DA, Reed JC, Kipps TJ. Thymidine-phosphorothioate oligonucleotides induce activation and apoptosis of CLL cells independently of CpG motifs or BCL-2 gene interference. Leukemia 2006; 20:680-8. PMID:16498393.
  269. Carew JS, Nawrocki ST, Krupnik YV, Dunner K, Jr., McConkey DJ, Keating MJ, Huang P. Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL. Blood 2006; 107:222-31. PMID:16144803.
  270. Calin GA, Garzon R, Cimmino A, Fabbri M, Croce CM. MicroRNAs and leukemias: how strong is the connection? Leuk Res 2006; 30:653-5. PMID:16330098.
  271. Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 2006; 66:7390-4. PMID:16885332.
  272. Calin GA, Croce CM. Genomics of chronic lymphocytic leukemia microRNAs as new players with clinical significance. Semin Oncol 2006; 33:167-73. PMID:16616063.
  273. Calin GA, Croce CM. MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene 2006; 25:6202-10. PMID:17028600.
  274. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6:857-66. PMID:17060945.
  275. Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM, Lampson B, Larson RA, Caligiuri MA, Heerema NA. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 2006; 24:437-43. PMID:16344317.
  276. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006; 107:1761-7. PMID:16269611.
  277. Brown JR, Kim HT, Li S, Stephans K, Fisher DC, Cutler C, Ho V, Lee SJ, Milford EL, Ritz J, Antin JH, Soiffer RJ, Gribben JG, Alyea EP. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant 2006; 12:1056-64. PMID:17084369.
  278. Binet JL, Caligaris-Cappio F, Catovsky D, Cheson B, Davis T, Dighiero G, Dohner H, Hallek M, Hillmen P, Keating M, Montserrat E, Kipps TJ, Rai K. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 2006; 107:859-61. PMID:16223776.





contact us home